Jim Simons
VOR icon

Jim Simons’s Vor Biopharma VOR Stock Holding History

Jim Simons’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3M Buy
+128,839
New +$1.82M ﹤0.01% 1830
2025
Q4 		– Sell
-14,600
Closed -$711K – 3796
2025
Q3 		$711K Sell
14,600
-8,806
-38% -$354K ﹤0.01% 2650
2025
Q2 		$758K Sell
23,406
-11,666
-33% -$103K ﹤0.01% 2636
2025
Q1 		$503K Buy
35,072
+8,597
+32% +$206K ﹤0.01% 2740
2024
Q4 		$588K Sell
26,475
-11,326
-30% -$188K ﹤0.01% 2770
2024
Q3 		$529K Buy
37,801
+13,036
+53% +$238K ﹤0.01% 2767
2024
Q2 		$495K Buy
24,765
+8,032
+48% +$260K ﹤0.01% 2694
2024
Q1 		$793K Buy
16,733
+14,153
+549% +$621K ﹤0.01% 2631
2023
Q4 		$116K Buy
2,580
+755
+41% +$31.2K ﹤0.01% 3266
2023
Q3 		$77K Buy
1,825
+5
+0.3% +$271 ﹤0.01% 3300
2023
Q2 		$112K Buy
1,820
+400
+28% +$36.5K ﹤0.01% 3444
2023
Q1 		$153K Sell
1,420
-878
-38% -$97.3K ﹤0.01% 3366
2022
Q4 		$306K Buy
2,298
+703
+44% +$69.6K ﹤0.01% 3210
2022
Q3 		$127K Buy
1,595
+730
+84% +$71.8K ﹤0.01% 3517
2022
Q2 		$86K Buy
+865
New +$88.5K ﹤0.01% 3886

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jim Simons's VOR Position: Q1 2026 in Review

Jim Simons opened a new position in Vor Biopharma (VOR) in Q1 2026: 128,839 shares worth $2.3M. The stake represents ﹤0.01% of the portfolio and ranks #1830 among its holdings. This is a return to the name: Jim Simons previously reported a position in VOR as recently as Q3 2025.

Jim Simons first reported a position in VOR in Q2 2022 and has held it in 15 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Jim Simons held 128,839 shares of Vor Biopharma worth $2.3M as of Q1 2026.
  • Vor Biopharma was a new Jim Simons position in Q1 2026.
  • Vor Biopharma made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1830 holding.
  • Jim Simons first reported a position in Vor Biopharma in Q2 2022 and has held it in 15 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.